AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. RPRX
  4. [Form 4] Royalty Pharma plc Insider Trading Activity

[Form 4] Royalty Pharma plc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc (RPRX), reported insider transactions on Form 4. The filing records an exempt acquisition of 3,696 Class A ordinary shares on 08/06/2025 in connection with the settlement of Equity Performance Awards under Rule 16b-3, recorded with a price of $0. The form also shows a reported disposition of 70,000 Class A ordinary shares (marked as a sale).

After the reported activity, the total beneficial ownership is reported as 652,342 shares, held indirectly through SCH Investment Partners LLC. The filing was signed by an attorney-in-fact on behalf of Mr. Hite.

Christopher Hite, EVP & Vice Chairman di Royalty Pharma plc (RPRX), ha segnalato operazioni di insider sul Form 4. La dichiarazione riporta un acquisto esente di 3,696 azioni ordinarie di Classe A in data 08/06/2025 in relazione alla liquidazione di Equity Performance Awards ai sensi della Rule 16b-3, registrato con un prezzo di $0. Il modulo mostra inoltre una cessione di 70,000 azioni ordinarie di Classe A (indicata come vendita).

Dopo le operazioni segnalate, la propriet脿 beneficiaria complessiva 猫 indicata in 652,342 azioni, detenute indirettamente tramite SCH Investment Partners LLC. Il filing 猫 stato firmato da un procuratore per conto del Sig. Hite.

Christopher Hite, EVP y Vicepresidente de Royalty Pharma plc (RPRX), inform贸 transacciones de insider en el Form 4. La presentaci贸n registra una adquisici贸n exenta de 3,696 acciones ordinarias Clase A el 08/06/2025 en relaci贸n con la liquidaci贸n de Equity Performance Awards bajo la Rule 16b-3, registrada con un precio de $0. El formulario tambi茅n muestra una disposici贸n de 70,000 acciones ordinarias Clase A (marcada como venta).

Tras la actividad reportada, la tenencia beneficiaria total se informa como 652,342 acciones, pose铆das de forma indirecta a trav茅s de SCH Investment Partners LLC. La presentaci贸n fue firmada por un apoderado en representaci贸n del Sr. Hite.

Christopher Hite, Royalty Pharma plc (RPRX)鞚� EVP 氚� 攵�須岇灔鞚� Form 4鞐� 雮措秬鞛� 瓯半灅毳� 鞁犼碃頄堨姷雼堧嫟. 頃措嫻 鞝滌稖靹滊姅 Rule 16b-3鞐� 霐半ジ Equity Performance Awards 鞝曥偘瓿� 甏�霠晿鞐� 氅挫牅霅� 旆摑鞙茧 3,696欤� Class A 氤错喌欤�毳� 08/06/2025鞐� 旆摑頄堨溂氅�, 臧�瓴╈潃 $0搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 靹滊鞐愲姅 霕愴暅 70,000欤� Class A 氤错喌欤检潣 觳橂秳鞚�(臧�) (毵る弰搿� 響滌嫓霅�) 鞁犼碃霅橃柎 鞛堨姷雼堧嫟.

鞁犼碃霅� 瓯半灅 鞚错泟 齑� 鞁れ 氤挫湢電� 652,342欤�搿� 氤搓碃霅橂┌, 鞚措姅 SCH Investment Partners LLC毳� 韱淀暣 臧勳爲 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊姅 Hite 鞌ゼ 雽�鞁犿暅 雽�毽澑 靹滊獏鞙茧 鞚措（鞏挫鞀惦媹雼�.

Christopher Hite, EVP et Vice-Chairman de Royalty Pharma plc (RPRX), a d茅clar茅 des op茅rations d'initi茅s sur le Form 4. Le d茅p么t indique une acquisition exon茅r茅e de 3,696 actions ordinaires de cat茅gorie A le 08/06/2025 dans le cadre du r猫glement d'Equity Performance Awards en vertu de la Rule 16b-3, enregistr茅e 脿 un prix de $0. Le formulaire montre 茅galement une cession de 70,000 actions ordinaires de cat茅gorie A (indiqu茅e comme une vente).

Apr猫s ces op茅rations, la d茅tention b茅n茅ficiaire totale est d茅clar茅e 脿 652,342 actions, d茅tenues indirectement via SCH Investment Partners LLC. Le d茅p么t a 茅t茅 sign茅 par un mandataire au nom de M. Hite.

Christopher Hite, EVP & Vice Chairman von Royalty Pharma plc (RPRX), meldete Insider-Transaktionen im Form 4. Die Einreichung weist einen befreiten Erwerb von 3,696 Class A Stammaktien am 08/06/2025 im Zusammenhang mit der Abwicklung von Equity Performance Awards gem盲脽 Rule 16b-3 aus, mit einem angegebenen Preis von $0. Das Formular zeigt au脽erdem eine gemeldete Ver盲u脽erung von 70,000 Class A Stammaktien (als Verkauf gekennzeichnet).

Nach den gemeldeten Transaktionen wird das Gesamtbeg眉nstigten-Eigentum mit 652,342 Aktien angegeben, die indirekt 眉ber SCH Investment Partners LLC gehalten werden. Die Einreichung wurde von einem Bevollm盲chtigten im Namen von Herrn Hite unterzeichnet.

Positive
  • Exempt acquisition of 3,696 shares via Rule 16b-3 shows compensation alignment through equity awards
  • Substantial reported beneficial ownership: 652,342 shares held indirectly via SCH Investment Partners LLC
Negative
  • Disposition of 70,000 shares is reported, representing insider selling that may prompt investor questions about liquidity or timing
  • Sale size relative to the disclosed holdings could be considered notable and may warrant monitoring in subsequent filings

Insights

TL;DR: Routine insider award settlement plus a significant sale reported; overall ownership remains sizeable at 652,342 shares.

The Form 4 records two routine types of insider activity: an exempt award settlement acquisition of 3,696 shares and a reported disposition of 70,000 shares. The acquisition is exempt under Rule 16b-3 and shows a $0 price, consistent with equity award settlement rather than an open-market purchase. The post-transaction beneficial ownership is listed as 652,342 shares, held indirectly via SCH Investment Partners LLC, indicating continued meaningful exposure despite the disposition. The combination of award vesting and sale is common in executive compensation cycles and requires context (e.g., size relative to holdings and timing) to assess impact on incentives and liquidity needs.

TL;DR: Transaction mix appears procedural: equity award settlement and insider sale; disclosure is standard and identifies indirect ownership vehicle.

The filing clearly attributes ownership to SCH Investment Partners LLC, which is useful for governance transparency. The exempt acquisition of 3,696 shares under Rule 16b-3 reflects internal compensation settlement practices and is disclosed appropriately. The reported 70,000-share disposition is a material-sized sale relative to common executive trades and should be noted by stakeholders reviewing insider liquidity and governance signals. Overall, disclosures conform to Section 16 requirements and describe the nature of indirect beneficial ownership.

Christopher Hite, EVP & Vice Chairman di Royalty Pharma plc (RPRX), ha segnalato operazioni di insider sul Form 4. La dichiarazione riporta un acquisto esente di 3,696 azioni ordinarie di Classe A in data 08/06/2025 in relazione alla liquidazione di Equity Performance Awards ai sensi della Rule 16b-3, registrato con un prezzo di $0. Il modulo mostra inoltre una cessione di 70,000 azioni ordinarie di Classe A (indicata come vendita).

Dopo le operazioni segnalate, la propriet脿 beneficiaria complessiva 猫 indicata in 652,342 azioni, detenute indirettamente tramite SCH Investment Partners LLC. Il filing 猫 stato firmato da un procuratore per conto del Sig. Hite.

Christopher Hite, EVP y Vicepresidente de Royalty Pharma plc (RPRX), inform贸 transacciones de insider en el Form 4. La presentaci贸n registra una adquisici贸n exenta de 3,696 acciones ordinarias Clase A el 08/06/2025 en relaci贸n con la liquidaci贸n de Equity Performance Awards bajo la Rule 16b-3, registrada con un precio de $0. El formulario tambi茅n muestra una disposici贸n de 70,000 acciones ordinarias Clase A (marcada como venta).

Tras la actividad reportada, la tenencia beneficiaria total se informa como 652,342 acciones, pose铆das de forma indirecta a trav茅s de SCH Investment Partners LLC. La presentaci贸n fue firmada por un apoderado en representaci贸n del Sr. Hite.

Christopher Hite, Royalty Pharma plc (RPRX)鞚� EVP 氚� 攵�須岇灔鞚� Form 4鞐� 雮措秬鞛� 瓯半灅毳� 鞁犼碃頄堨姷雼堧嫟. 頃措嫻 鞝滌稖靹滊姅 Rule 16b-3鞐� 霐半ジ Equity Performance Awards 鞝曥偘瓿� 甏�霠晿鞐� 氅挫牅霅� 旆摑鞙茧 3,696欤� Class A 氤错喌欤�毳� 08/06/2025鞐� 旆摑頄堨溂氅�, 臧�瓴╈潃 $0搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 靹滊鞐愲姅 霕愴暅 70,000欤� Class A 氤错喌欤检潣 觳橂秳鞚�(臧�) (毵る弰搿� 響滌嫓霅�) 鞁犼碃霅橃柎 鞛堨姷雼堧嫟.

鞁犼碃霅� 瓯半灅 鞚错泟 齑� 鞁れ 氤挫湢電� 652,342欤�搿� 氤搓碃霅橂┌, 鞚措姅 SCH Investment Partners LLC毳� 韱淀暣 臧勳爲 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊姅 Hite 鞌ゼ 雽�鞁犿暅 雽�毽澑 靹滊獏鞙茧 鞚措（鞏挫鞀惦媹雼�.

Christopher Hite, EVP et Vice-Chairman de Royalty Pharma plc (RPRX), a d茅clar茅 des op茅rations d'initi茅s sur le Form 4. Le d茅p么t indique une acquisition exon茅r茅e de 3,696 actions ordinaires de cat茅gorie A le 08/06/2025 dans le cadre du r猫glement d'Equity Performance Awards en vertu de la Rule 16b-3, enregistr茅e 脿 un prix de $0. Le formulaire montre 茅galement une cession de 70,000 actions ordinaires de cat茅gorie A (indiqu茅e comme une vente).

Apr猫s ces op茅rations, la d茅tention b茅n茅ficiaire totale est d茅clar茅e 脿 652,342 actions, d茅tenues indirectement via SCH Investment Partners LLC. Le d茅p么t a 茅t茅 sign茅 par un mandataire au nom de M. Hite.

Christopher Hite, EVP & Vice Chairman von Royalty Pharma plc (RPRX), meldete Insider-Transaktionen im Form 4. Die Einreichung weist einen befreiten Erwerb von 3,696 Class A Stammaktien am 08/06/2025 im Zusammenhang mit der Abwicklung von Equity Performance Awards gem盲脽 Rule 16b-3 aus, mit einem angegebenen Preis von $0. Das Formular zeigt au脽erdem eine gemeldete Ver盲u脽erung von 70,000 Class A Stammaktien (als Verkauf gekennzeichnet).

Nach den gemeldeten Transaktionen wird das Gesamtbeg眉nstigten-Eigentum mit 652,342 Aktien angegeben, die indirekt 眉ber SCH Investment Partners LLC gehalten werden. Die Einreichung wurde von einem Bevollm盲chtigten im Namen von Herrn Hite unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hite Christopher
(Last) (First) (Middle)
C/O ROYALTY PHARMA PLC
110 E. 59TH STREET
(Street)
NEW YORK NY 10022
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & Vice Chairman
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Ordinary Shares 08/06/2025 A 3,696(1) A $0 652,342 I By SCH Investment Partners LLC
Class A Ordinary Shares 70,000 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
Remarks:
/s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite 08/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transactions did Christopher Hite report on Form 4 for RPRX?

The Form 4 reports an exempt acquisition of 3,696 Class A ordinary shares and a reported disposition of 70,000 Class A ordinary shares.

When was the acquisition of shares recorded on the Form 4?

The acquisition is recorded with a transaction date of 08/06/2025 and is described as a settlement of Equity Performance Awards under Rule 16b-3.

What price is shown for the acquisition of the 3,696 shares?

The acquisition is recorded with a price of $0, consistent with settlement of equity awards rather than a cash purchase.

How many Royalty Pharma shares does the filing show beneficially owned after the transactions?

The filing reports 652,342 shares beneficially owned following the reported transaction(s), held indirectly via SCH Investment Partners LLC.

What is the reporting person's role at Royalty Pharma?

The reporting person, Christopher Hite, is identified as EVP & Vice Chairman of Royalty Pharma plc.
Stock RPRX logo
Royalty Pharma Plc

NASDAQ:RPRX

RPRX Rankings

#670 Ranked by Market Cap
#1428 Ranked by Dividends

RPRX Latest News

Aug 13, 2025
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
Aug 6, 2025
Royalty Pharma Reports Second Quarter 2025 Results
Jul 18, 2025
Royalty Pharma Declares Third Quarter 2025 Dividend
Jul 17, 2025
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company鈥檚 Board of Directors
Jul 16, 2025
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025

RPRX Latest SEC Filings

Aug 14, 2025
[SCHEDULE 13G/A] Royalty Pharma plc SEC Filing
Aug 13, 2025
[8-K] Royalty Pharma plc Reports Material Event
Aug 13, 2025
[SCHEDULE 13G] Royalty Pharma plc SEC Filing
Aug 11, 2025
[Form 4] Royalty Pharma plc Insider Trading Activity
Aug 11, 2025
[144] Royalty Pharma plc SEC Filing

RPRX Stock Data

15.64B
393.15M
8.93%
82.61%
3.97%
Biotechnology
Pharmaceutical Preparations
United States
NEW YORK